Dr. Sachiko Ezawa
Dr. Ezawa joined the Obstetrics & Gynecology department of Keio University Hospital in 1998. She went to business school while practicing medicine and established GenomLab, a supplement company.
Her research, ‘Response of glassy-cell carcinoma of the cervix’ was published in The Lancet in 2000. After further clinical experience gained at Saiseikai Central Hospital, Tokyo in 2001 and National Tochigi Hospital, Tochigi in 2002. She returned to Keio University Hospital as an Ovarian cancer surgeon, during this period. She studied “Anti tumor effects of a novel retinoid, TAC-101” towards clear cell adeno carcinoma of the ovary which was subsequently published in “Gynecologic Oncology 2007” this research was the main subject of her PhD which was awarded by Keio University in 2008.
Dr.Ezawa was a lead ovarian and cervical cancer surgeon when she completed her tenure at Keio University Hospital. After University hospital, she became the only woman NASA/JAXA finalist of astronaut training program in 2009. After NASA, she is currently studying law and medicine and while continuing to be a clinical doctor.
Ezawa S, Suzuki N, Ohie S,Higasiguchi A, Hosoi F,Kitazato K,Susumu N,Aoki D. A synthetic retionoid,TAC-101(4-[3,5-bis(trimethysilyl)benzamido]benzoic acid),plus cisplatin:Potential new therapy for ovarian clear cell adenocarcinoma Gynecologic Oncology.2007 Nov 27;:18048092
Mikami M,Ezawa S,Sakaiya N,Komuro Y,Tei C,Fukuchi T Response of glassy-cell carcinoma of the cervix to cisplatin, epirubicin, and mitomycin C. The lancet 2000;:13(3):127-133